Eikon Therapeutics, Inc. (EIKN) shareholders
Close on Nov 17, 2026Market cap $278.95MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Tim Kutzkey Joint filing with Peter Svennilson (11.60%), The Column Group IV GP, LP (8.30%) and 1 more | 6,353,712 | 11.60% | 13D (active) | Feb 6, 2026 |
| FMR LLC Joint filing with Abigail P. Johnson (10.20%) | 5,520,152 | 10.20% | 13G (passive) amendment | Sep 30, 2026 |
| Abigail P. Johnson Joint filing with FMR LLC (9.20%) | 4,993,906 | 9.20% | 13G (passive) amendment | Jun 30, 2026 |
| James B. Tananbaum | 4,148,519 | 7.70% | 13G (passive) | Feb 4, 2026 |
| BlackRock Portfolio Management LLC | 3,002,737 | 5.50% | 13G (passive) | Mar 31, 2026 |
| Perlmutter Roger M | 2,893,171 | 5.20% | 13G (passive) | Feb 4, 2026 |
| Abu Dhabi Investment Authority | 2,816,714 | 5.20% | 13G (passive) | Feb 4, 2026 |
| Innovation Endeavors III GP, LLC Joint filing with Innovation Endeavors III LP (5.00%) | 2,723,226 | 5.00% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of EIKN | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 4,993,906 | 9.22% | $65.17M | +1,157,076 | 0.00% |
| BlackRock, Inc. | 4,281,425 | 7.90% | $55.87M | +962,046 | 0.00% |
| Foresite Capital Management IV, LLC | 1,943,682 | 3.59% | $25.37M | – | 8.74% |
| Merck & Co., Inc. | 1,666,666 | 3.08% | $21.75M | – | 4.13% |
| T. Rowe Price Investment Management, Inc. | 1,595,274 | 2.95% | $20.82M | +372,787 | 0.01% |
| Foresite Capital Management V, LLC | 1,318,983 | 2.44% | $17.21M | – | 4.75% |
| Capital World Investors | 1,175,944 | 2.17% | $15.35M | +32,307 | 0.00% |
| Price T Rowe Associates Inc /Md/ | 1,005,035 | 1.86% | $13.12M | +29,201 | 0.00% |
| Vanguard Capital Management LLC | 922,707 | 1.70% | $12.04M | −46,724 | 0.00% |
| EcoR1 Capital, LLC | 732,606 | 1.35% | $9.56M | – | 0.46% |
| Alliancebernstein L.P. | 641,888 | 1.19% | $6.79M | −380,300 | 0.00% |
| Geode Capital Management, LLC | 556,955 | 1.03% | $7.27M | +283,024 | 0.00% |
| Baker Bros. Advisors LP | 555,555 | 1.03% | $7.25M | – | 0.04% |
| Soros Capital Management LLC | 484,672 | 0.89% | $6.32M | – | 1.13% |
| StepStone Group LP | 395,340 | 0.73% | $5.16M | – | 0.24% |
| Canada Pension Plan Investment Board | 379,024 | 0.70% | $4.95M | – | 0.00% |
| State Street Corp | 354,093 | 0.65% | $4.62M | +313,943 | 0.00% |
| Franklin Resources Inc | 350,000 | 0.65% | $4.57M | – | 0.00% |
| General Catalyst Group Management, LLC | 305,233 | 0.56% | $3.98M | – | 2.11% |
| UBS Group AG | 263,932 | 0.49% | $3.44M | +164,524 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 77 | 27M | 48.9% | 37 / 17 | 9 / 12 | 5M | 2M |
| Q1 2026 | 52 | 24M | 43.8% | 52 / 0 | 0 / 0 | 24M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of EIKN | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Contrafund | 1,275,800 | 2.36% | $16.65M | 0.01% | Jun 30, 2026 |
| SMALLCAP World Fund Inc | 1,143,637 | 2.11% | $14.92M | 0.02% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 974,333 | 1.80% | $10.56M | 0.20% | May 31, 2026 |
| T. Rowe Price Small-Cap Value Fund, Inc. | 926,046 | 1.71% | $12.08M | 0.11% | Jun 30, 2026 |
| BlackRock Health Sciences Opportunities Portfolio | 722,389 | 1.33% | $7.83M | 0.13% | May 29, 2026 |
| Vanguard Total Stock Market Index Fund | 660,117 | 1.22% | $8.61M | 0.00% | Jun 30, 2026 |
| Fidelity Growth Company Fund | 602,300 | 1.11% | $6.53M | 0.01% | May 31, 2026 |
| iShares Russell 2000 ETF | 510,661 | 0.94% | $6.66M | 0.01% | Jun 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 349,098 | 0.64% | $4.56M | 0.04% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 331,011 | 0.61% | $4.32M | 0.03% | Jun 30, 2026 |
| Fidelity Contrafund K6 | 265,469 | 0.49% | $3.46M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 237,756 | 0.44% | $2.19M | 0.01% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 235,174 | 0.43% | $3.07M | 0.00% | Jun 30, 2026 |
| Fidelity Growth Company K6 Fund | 169,228 | 0.31% | $1.83M | 0.01% | May 31, 2026 |
| Fidelity Series Growth Company Fund | 154,400 | 0.29% | $1.67M | 0.01% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Roger M. Perlmutter | See remarks, Director | 1,475,856 | 2.72% | Mar 4, 2026 |
| Roy D. Baynes | Chief Medical Officer | – | – | Mar 4, 2026 |
| Michael A. Klobuchar | Chief Operating Officer | – | – | Mar 4, 2026 |
| Benjamin Bruno Thorner | See Remarks | – | – | Mar 4, 2026 |
| Alfred Lloyd Bowie Jr. | Chief Financial Officer | 51,572 | 0.10% | Mar 4, 2026 |
| Ma. Fatima Francisco | Director | – | – | Jun 15, 2026 |
| Kenneth C. Frazier | Director | 111,111 | 0.21% | Mar 4, 2026 |
| Robert Luther Huffines | Director | – | – | Mar 4, 2026 |
| Josh Wolfe | Director, 10% owner | 2,387,705 | 4.41% | Feb 6, 2026 |
| David W. Meline | Director | – | – | Feb 4, 2026 |
| Leon Chen | Director | – | – | Feb 4, 2026 |
| Tim Kutzkey | 10% owner | 5,869,343 | 10.84% | Sep 8, 2026 |
| TCG Opportunity III GP, LLC | 10% owner | – | – | Sep 8, 2026 |
| Column Group Opportunity III GP, LP | 10% owner | – | – | Sep 8, 2026 |
| Column Group IV-A, LP | 10% owner | – | – | Sep 8, 2026 |
| Column Group IV, LP | 10% owner | – | – | Sep 8, 2026 |
| Column Group Opportunity III, LP | 10% owner | 3,658,598 | 6.75% | Sep 8, 2026 |
| Peter Svennilson | 10% owner | – | – | Sep 8, 2026 |
| Column Group IV GP, LP | 10% owner | – | – | Sep 8, 2026 |
| Foresite Capital Opportunity Management V, LLC | 10% owner | 1,676,399 | 3.09% | Feb 6, 2026 |
| Foresite Capital Opportunity Fund V, L.P. | 10% owner | – | – | Feb 6, 2026 |
| Peter Hebert | 10% owner | – | – | Feb 6, 2026 |
| Foresite Capital Fund IV, L.P. | 10% owner | – | – | Feb 6, 2026 |
| Foresite Capital Management IV, LLC | 10% owner | – | – | Feb 6, 2026 |
| Foresite Capital VI-A, LLC | 10% owner | – | – | Feb 6, 2026 |
| Lux Ventures V, L.P. | 10% owner | 2,387,705 | 4.41% | Feb 6, 2026 |
| Lux Total Opportunities, L.P. | 10% owner | – | – | Feb 6, 2026 |
| Lux Venture Partners V, LLC | 10% owner | – | – | Feb 6, 2026 |
| Lux Co-Invest Opportunities II, L.P. | 10% owner | – | – | Feb 6, 2026 |
| Foresite Capital VI-A Management, LLC | 10% owner | – | – | Feb 6, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Tim Kutzkey 10% owner | Sep 3, 2026 | Buy | +89,200 | $11.56 | $1.03M | 89,200 |
| Roger M. Perlmutter See remarks, Director | Feb 6, 2026 | Conversion | +284,857 | – | – | 284,857 |
| Column Group Opportunity III, LP 10% owner | Feb 6, 2026 | Conversion | +47,898 | – | – | 95,499 |
| Column Group Opportunity III, LP 10% owner | Feb 6, 2026 | Conversion | +44,249 | – | – | 47,601 |
| Column Group Opportunity III, LP 10% owner | Feb 6, 2026 | Conversion | +110,928 | – | – | 2,874,816 |
| Column Group Opportunity III, LP 10% owner | Feb 6, 2026 | Conversion | +1,403,568 | – | – | 2,763,888 |
| Column Group Opportunity III, LP 10% owner | Feb 6, 2026 | Conversion | +1,296,629 | – | – | 1,360,320 |
| Column Group Opportunity III, LP 10% owner | Feb 6, 2026 | Buy | +1,437,323 | $18.00 | $25.87M | 4,312,139 |
| Column Group Opportunity III, LP 10% owner | Feb 6, 2026 | Buy | +49,556 | $18.00 | $892.01K | 148,840 |
| Column Group Opportunity III, LP 10% owner | Feb 6, 2026 | Conversion | +3,785 | – | – | 99,284 |
| Column Group Opportunity III, LP 10% owner | Feb 6, 2026 | Conversion | +688,283 | – | – | 688,283 |
| Column Group Opportunity III, LP 10% owner | Feb 6, 2026 | Buy | +630,881 | $18.00 | $11.36M | 1,319,164 |
| Josh Wolfe Director, 10% owner | Feb 6, 2026 | Conversion | +2,387,705 | – | – | 2,387,705 |
| Josh Wolfe Director, 10% owner | Feb 6, 2026 | Conversion | +1,151,540 | – | – | 1,290,428 |
| Josh Wolfe Director, 10% owner | Feb 6, 2026 | Conversion | +2,155,765 | – | – | 2,294,653 |
| Lux Ventures V, L.P. 10% owner | Feb 6, 2026 | Conversion | +2,387,705 | – | – | 2,387,705 |
| Lux Ventures V, L.P. 10% owner | Feb 6, 2026 | Conversion | +1,151,540 | – | – | 1,290,428 |
| Lux Ventures V, L.P. 10% owner | Feb 6, 2026 | Conversion | +2,155,765 | – | – | 2,294,653 |
| Kenneth C. Frazier Director | Feb 4, 2026 | Buy | +111,111 | $18.00 | $2.00M | 111,111 |
| Foresite Capital Opportunity Management V, LLC 10% owner | Feb 4, 2026 | Conversion | +335,521 | – | – | 1,676,399 |
| Foresite Capital Opportunity Management V, LLC 10% owner | Feb 4, 2026 | Conversion | +408,725 | – | – | 408,725 |
| Foresite Capital Opportunity Management V, LLC 10% owner | Feb 4, 2026 | Conversion | +38,133 | – | – | 425,852 |
| Foresite Capital Opportunity Management V, LLC 10% owner | Feb 4, 2026 | Conversion | +922 | – | – | 387,719 |
| Foresite Capital Opportunity Management V, LLC 10% owner | Feb 4, 2026 | Conversion | +37,855 | – | – | 386,797 |
| Foresite Capital Opportunity Management V, LLC 10% owner | Feb 4, 2026 | Conversion | +348,942 | – | – | 348,942 |
| Foresite Capital Opportunity Management V, LLC 10% owner | Feb 4, 2026 | Conversion | +458,855 | – | – | 1,263,428 |
| Foresite Capital Opportunity Management V, LLC 10% owner | Feb 4, 2026 | Conversion | +67,207 | – | – | 804,573 |
| Foresite Capital Opportunity Management V, LLC 10% owner | Feb 4, 2026 | Conversion | +1,626 | – | – | 737,366 |
| Foresite Capital Opportunity Management V, LLC 10% owner | Feb 4, 2026 | Conversion | +37,855 | – | – | 735,740 |
| Foresite Capital Opportunity Management V, LLC 10% owner | Feb 4, 2026 | Conversion | +697,885 | – | – | 697,885 |
| Foresite Capital Opportunity Management V, LLC 10% owner | Feb 4, 2026 | Conversion | +229,428 | – | – | 1,943,682 |
| Foresite Capital Opportunity Management V, LLC 10% owner | Feb 4, 2026 | Conversion | +37,855 | – | – | 1,714,254 |
| Foresite Capital Opportunity Management V, LLC 10% owner | Feb 4, 2026 | Buy | +55,555 | $18.00 | $999.99K | 1,318,983 |
| Foresite Capital Opportunity Management V, LLC 10% owner | Feb 4, 2026 | Conversion | +1,340,878 | – | – | 1,340,878 |
| Josh Wolfe Director, 10% owner | Feb 4, 2026 | Buy | +138,888 | $18.00 | $2.50M | 138,888 |
| Josh Wolfe Director, 10% owner | Feb 4, 2026 | Buy | +138,888 | $18.00 | $2.50M | 138,888 |
| Lux Ventures V, L.P. 10% owner | Feb 4, 2026 | Buy | +138,888 | $18.00 | $2.50M | 138,888 |
| Lux Ventures V, L.P. 10% owner | Feb 4, 2026 | Buy | +138,888 | $18.00 | $2.50M | 138,888 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 9 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Eikon Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 60,968 shares on Sep 25, 2026 over the last 90 days.
See a number that looks wrong?